

## Company Profile

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

## Executive Board



**Matthias Gärtner,**  
CEO



**Falk Neukirch,**  
CFO



**Mi-Young Miehler,**  
COO





**Christoph Prußeit,**  
CINO




**Constantijn van Rietschoten,**  
CIM


## Structure and Segments



## Consolidated Revenue in €m



## Consolidated EBITDA pre\* in €m



<sup>1</sup> Full Year; <sup>2</sup> Including the segment "Services" (-13.2% in FY 2023); \* adjusted for extraordinary expenses (EBITDA pre); \*\* pro forma; CAGR = Compound Annual Growth Rate.

Contact:  
[ir@medios.group](mailto:ir@medios.group)  
[www.medios.group](http://www.medios.group)

## Key Figures

in €m	2023 (IFRS)	2022 (IFRS)	Change
Sales	1,784.7	1,610.8	+10.8%
EBITDA pre*	60.5	54.9	+10.3%
Margin in %	3.4	3.4	+0.0

\*adjusted for extraordinary expenses

## Basic Information

Share Capital	€25,505,723
No. of shares	25,505,723
Share class	No-par value bearer shares
WKN/ISIN	A1MMCC/DE000A1MMCC8 / DE000A409682*
Trading places	Regulated Market Frankfurt (Prime Standard)

\* Note pursuant to Sec. 7 German Stock Exchange Admission Regulation (Börsenzulassungsverordnung – BörsZulV): From a capital increase in kind registered with the commercial register on 11 June 2024, 1,700,000 newly issued shares came into existence, which bear a separate ISIN (DE000A409682) and which are currently not admitted to trading.


## Shareholder Structure

All figures according to voting rights notifications of the notifying parties

**58.5%**

### Free float

- 4.9% Paladin Asset Management investment stock corporation with variable capital and sub-funds
- 4.7% SEB Investment Management AB



**19.7%**

### Martin Hesse

incl. attribution of  
BMSH GmbH

**15.1%**

### Luxempart Invest S.á.r.l.

**6,7%**

### Bencis Capital Partners B.V.

## Share Price in €

